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Purpose: To evaluate the morphologic effects of intravitreal triamcinolone acetonide
(TA) on rabbit retina.
Methods: Intravitreal injections of 0.5 mg, 1 mg, 4 mg, 8 mg, and 20 mg of TA
(Kenalog-40; Bristol-Myers Squibb, Princeton, NJ) in 0.1 mL were given to pigmented
rabbits. For control, 0.1 mL of TA vehicle and saline were injected. Animals were killed on
day 14, and retinas were analyzed by light as well as electron microscopy.
Results: No ophthalmoscopic change was found. Eyes injected with 0.5 mg and 1 mg
of TA did not have morphologic abnormality. Eyes injected with 4 mg, 8 mg, and 20 mg
showed destruction of photoreceptor outer segments and migration of macrophage-like
cells in the subretinal space. Eyes injected with 20 mg showed more extensive damage
and increased pigment granules in the retinal pigment epithelium cells with large oil
droplets in the cytoplasm. Electron microscopy also showed loss of photoreceptor/retinal
pigment epithelium interdigitations. Eyes injected with vehicle or saline did not show
morphologic changes.
Conclusion: Single intravitreal injection of 0.5 mg or 1 mg of TA did not produce
morphologic retinal changes in pigmented rabbits. However, injections of 4 mg, 8 mg, and
20 mg of TA produced outer retina toxic effects. These findings suggest that long-term
retinal toxicity studies should be carried out, using single and repeated injections before
this therapy becomes more widely used.
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Intravitreal injection of triamcinolone acetonide(TA) has been largely used as an alternative in the
treatment of macular edema secondary to diabetes,
retinal vascular occlusion, uveitis, and Irvine–Gass
syndrome.1–5 In addition, TA has been proposed as
adjunctive treatment for exudative age-related macu-
lar degeneration, proliferative vitreoretinopathy, and
uveitis because of its antiangiogenic, antiproliferative,
and antiinflammatory properties.6–9
Drug delivery into the posterior segment of the eye
alleviates some issues, such as intraocular penetration
and bioavailability, and can lead to improved thera-
peutic effect by increasing the intraocular drug con-
centration.10,11 However, it can be associated with a
higher risk of local toxicity. The ocular side effects of
topical steroids are well known and include posterior
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subcapsular cataract and elevation of ocular pres-
sure.12 More recently, several case series on compli-
cations after intravitreal injection of TA have been
reported, including ocular hypertension and infectious
or sterile endophthalmitis.13–17 However, there is little
information on the effect of TA on the retina.
Previous animal studies did not show retinal toxic-
ity after intravitreal injection of up to 4 mg of TA,18–21
but even higher doses have been used clinically.1–4,6–9
The purpose of this study was to evaluate morphologic
changes on pigmented rabbit retina caused by intrav-
itreal injection of TA (Kenalog-40; Bristol-Myers




Twenty-four Dutch Belted rabbits (weight, 2–3 kg)
were used in this study. All animals were treated in
accordance with the Association for Research in Vi-
sion and Ophthalmology Statement for the Use of
Animals in Ophthalmic and Vision Research, and the
experiments were approved by the Animal Care Com-
mittee of the Massachusetts Eye and Ear Infirmary
(Boston, MA). Animals were anesthetized with intra-
muscular injection of 50 mg/kg ketamine hydrochlo-
ride and 5 mg/kg xylazine hydrochloride, and pupils
were dilated with topical 2.5% phenylephrine. Topical
anesthesia was achieved with 0.5% proparacaine. An-
imals were divided in 7 groups: 0.5 mg of TA (3 eyes),
1 mg of TA (3 eyes), 4 mg of TA (4 eyes), 8 mg of TA
(4 eyes), 20 mg of TA (4 eyes), vehicle (2 eyes), and
saline (4 eyes). Contralateral eyes were left un-
touched.
TA Preparation
TA (Kenalog-40 [40 mg/mL TA, 0.99% (w/v) ben-
zyl alcohol, 0.75% carboxymethylcellulose sodium,
and 0.04% polysorbate 80]; Bristol-Myers Squibb)
was used. The drug was prepared in a 1-mL tuberculin
syringe. A volume of 0.1 mL was injected in the eye.
For 0.5-mg and 1-mg injections, 0.1 mL of the
original suspension was diluted with 0.7 mL and 0.3
mL of sterile saline for injection, respectively, and 0.1
mL of the new suspension was injected into the vit-
reous. For 4-mg injections, 0.1 mL of the original
suspension was injected. For 8-mg and 20-mg injec-
tions, 1 mL of the original suspension was drawn up
into the syringe and kept in a vertical position with the
needle turned up for 30 minutes, until TA settled
down. Then, 0.5 mL and 0.8 mL of the supernatant
(vehicle), respectively, was discarded. The remaining
suspension was mixed, and 0.1 mL was injected into
the vitreous. Vehicle was prepared as described above
for 8-mg and 20-mg injections.
Intravitreal Injection
Before injections, eyes were dilated, and paracen-
tesis with removal of 0.1 mL of aqueous humor was
performed using a 1-mL syringe with a 30-gauge
needle, to avoid an increase in intraocular pressure.
Intravitreal injection of 0.1 mL of solution was per-
formed with a 1-mL syringe with a 27-gauge needle,
slowly and under direct observation with a stereo-
scopic microscope, directed to the center of the vitre-
ous cavity.
Ocular and Histologic Examination
Animals underwent slit-lamp biomicroscopy, indi-
rect ophthalmoscopy, and fundus photography before
and immediately after injection and on days 1, 3, 7,
and 14. All animals were killed on day 14 with intra-
venous injection of phenobarbital sodium solution
(Fatal-Plus; Vortech Pharmaceuticals, Dearborn, MI).
Immediately after death, eyes were enucleated, the
anterior segment with the lens was removed, and the
posterior segment was fixed in 50% Karnovsky (Elec-
tron Microscopy Sciences, Fort Washington, PA) for
24 hours. After fixation, 5 ! 5-mm pieces of the
inferior midperipheral posterior segment (retina/cho-
roid/sclera) were processed for light microscopy (BHS
System; Olympus Optical, Tokyo, Japan) and trans-
mission electron microscopy (Philips 410 EM; Philips
Electron Optics, Eindhoven, Holland). Light micros-
copy sections were stained with phenylenediamine,
and transmission electron microscopy sections were
stained with lead and uranyl acetate.
Results
In all TA-injected eyes, the drug crystals settled
within the cortical vitreous overlying the inferior mid-
peripheral retina as a white mass. Its volume became
progressively smaller, but the shrinkage was slow,
remaining visible on day 14. Two eyes (4 mg and 8
mg) developed a mild anterior chamber reaction that
resolved within 1 week. Another eye (8 mg) devel-
oped cataract due to accidental touch of the anterior
lens capsule with the needle during paracentesis. No
vitreous cells or retinal lesions such as retinal whiten-
ing, hemorrhage, or pigmentary changes were noted.
Eyes injected with 0.5 mg and 1 mg of TA did not
show any morphologic change during light micros-
copy, as well as eyes injected with vehicle (Fig. 1A)
and saline. However, eyes injected with 4 mg, 8 mg,
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and 20 mg of TA had dose-dependent changes in the
outer retina, such as loss of photoreceptor outer seg-
ments and disorganization of the outer segment layer,
with macrophage-like cells in the subretinal space,
particularly in areas with increased outer segment
disorganization (Fig. 1, B and C). Retinal pigment
epithelium (RPE) cells appeared hypertrophic, with
increased pigment granules clustered in the cyto-
plasm. Amorphous material was in the subretinal
space (Fig. 1, B and C). These findings were more
evident in eyes injected with 20 mg of TA. In addition,
RPE cells of 20-mg injected eyes displayed abundant
large oil droplets (Fig. 1C).
Transmission electron microscopy confirmed these
findings. Ultrastructures of the eyes injected with 0.5
mg and 1 mg of TA, vehicle, and saline were normal.
However, 4-mg-, 8-mg-, and 20-mg-injected eyes had
disruption of photoreceptor outer segments with ne-
crotic cellular debris within the subretinal space. Mac-
rophages in the subretinal space had lamellar and
homogeneous inclusions (Fig. 2), and large lipid drop-
lets were seen in the RPE cells. The inner retina
appeared normal. In eyes injected with 20 mg of TA,
photoreceptor outer segment disruption with loss of
the photoreceptor/RPE interdigitation was prominent;
clusters of hyperplastic and hypertrophic RPE cells
packed with pigment granules and large oil droplets
were seen (Fig. 3A). Macrophages displayed in-
creased cytoplasmic inclusions (Fig. 3B).
Discussion
Recent reports and presentations have shown wide-
spread use of intravitreal TA injections despite lack of
convincing safety data as well as randomized clinical
trials of long-term efficacy. In this study, we analyzed
the morphologic effects of single intravitreal injec-
tions of Kenalog-40 (the TA preparation used in the
United States) at doses commonly used in clinical
Fig. 1. Light micrographs 14 days after single intravitreal injection of
vehicle (A) and of 4 mg (B) and 20 mg (C) of triamcinolone acetonide.
A, Well preserved retinal morphology. B, Macrophage-like cell (arrow)
on the retinal pigment epithelium (RPE) surface. C, Increased number
of macrophage-like cells (arrows), prominent clustering of pigment
granules, and enlarged lipid droplets in the RPE cells (asterisks) (stain,
phenylenediamine; original magnification, !400).
Fig. 2. Electron micrograph 14 days after single intravitreal injection
of 4 mg of triamcinolone acetonide. Disruption of photoreceptor outer
segments with necrotic cellular debris within the subretinal space and
a macrophage in the subretinal space with lamellar inclusions (original
magnification, !1,600).
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practice. Our study suggests that TA is toxic to rabbit
retina in doses as low as 4 mg. Eyes injected with
doses of 4 mg, 8 mg, and 20 mg of TA showed
dose-dependent structural changes in the outer retina,
such as photoreceptor outer segment disruption, accu-
mulation of amorphous cellular debris, and migration
of macrophage-like cells in the subretinal space. Hy-
perplastic and hypertrophic RPE cells with increased
pigment granules and large lipid droplets were also
present in these eyes.
In our laboratory, we previously demonstrated ret-
inal toxicity in pigmented rabbits after intravitreal
injections of dexamethasone.22 With 400 !g, transient
Mu¨ller cell swelling was observed. However, with
larger doses, permanent photoreceptor outer segment
disintegration with accumulation of amorphous gran-
ules on the surface of the RPE layer was found. Mu¨ller
cells were suggested as the primary site of damage.
This work supported earlier findings of Shimada and
Matsui,23 who showed retinal degeneration confined
to the inferior region of the fundus after a 10-mg
dexamethasone injection.
This study demonstrated that doses as low as 4 mg
of TA injected in the vitreous produced morphologic
changes in rabbit retina. Other than a meeting presen-
tation (American Society of Retina Specialists, 2003;
602), none of the few reported studies showed retinal
toxicity with doses as high as 4 mg.18–21,24–26 McCuen
et al18 did not find histologic or functional signs of
retinal toxicity after injection of 1 mg of TA in pig-
mented rabbit eyes in a 3-month follow-up. Hui et al19
injected 1 mg, 2 mg, and 4 mg of TA and did not find
any signs of toxicity with both light microscopy and
electron microscopy. In our study, we confined the
tissue analysis to the inferior retina, because after
intravitreal injection the drug settles inferiorly, where
maximal concentration is expected. This may explain
why we found toxic effects with 4 mg of TA while
other previously reported studies did not. Another
difference among this study and the others was the
time point (14 days in our study vs. 3 months18 and 28
days19). Although the follow-up in this study was
shorter and we examined only one time point, it seems
unlikely that the findings described here could be
reversible in nature.
Kivilcim et al21 also studied the retinal toxicity of 1
mg, 2 mg, and 4 mg of TA in vitrectomized, silicone-
filled albino rabbit eyes and showed no morphologic
or electroretinographic changes with these doses. In
this case, comparison with our results is inappropriate
because of differences of pigmentation between the
rabbit species used as well as because vitrectomy
changes the dynamics and pharmacokinetic of the
drug inside the eye. Another difference is the time
point: Kivilcim et al21 killed the animals when no drug
was visible in the vitreous cavity, while we killed the
animals 14 days after the injection.
Our results show damage to the outer retina by TA.
In doses as low as 4 mg of TA, disorganization of the
photoreceptor outer segments of different degrees was
noted. Photoreceptor injury leads to increased shed-
ding of cellular debris into the subretinal space, and
with the accumulation of necrotic cellular debris, the
macrophages migrate into the subretinal space. In
addition, it is possible that the RPE cells are also
damaged, as suggested by the in vitro experiments of
Yeung et al.27 Furthermore, TA may produce loss of
the crucial interdigitation between the outer segments
and the apical RPE microvilli, followed by outer seg-
ment degeneration. TA may also have an inhibitory
effect on the RPE phagocytosis and lysosomal activ-
ity, as demonstrated by Uyama et al28 in cultured RPE
cells; the increased number of large lipid droplets seen
in the 20-mg treated eyes in our study may have been
Fig. 3. Electron micrographs
14 days after single intravit-
real injection of 20 mg of tri-
amcinolone acetonide. A,
Photoreceptor outer segment
disruptions are seen in associ-
ation with loss of the photo-
receptor/retinal pigment epi-
thelium (RPE) interdigitation.
The RPE cells show large
lipid droplets (asterisks) and
pigment granules (original
magnification, !1,600). B, A
macrophage-like cell packed
with cytoplasmic inclusions is
shown (original magnifica-
tion, !2,400).
534 RETINA, THE JOURNAL OF RETINAL AND VITREOUS DISEASES ● 2006 ● VOLUME 26 ● NUMBER 5
caused by the decreased lysosomal activity in the RPE
cells.
Some investigators believe that retinal toxicity as-
sociated with TA may be due to its vehicle, benzyl
alcohol.18,29 In our model, eyes injected with vehicle
alone did not show any toxicity. Similarly, Hida et al30
and Morrison et al (Association for Research in Vision
and Ophthalmology, 2004; 1917) demonstrated no
retinal toxicity of benzyl alcohol at the concentration
used in clinical practice, reinforcing our findings. Hida
et al30 also showed no associated toxicity with twice
the concentration of benzyl alcohol found in the Ke-
nalog suspension, and Morrison et al (Association for
Research in Vision and Ophthalmology, 2004; 1917)
showed toxicity only with higher concentrations
("3.3 times). In addition, Yeung et al27 did not detect
any in vitro toxic effect of benzyl alcohol on RPE
cells. Interestingly, in a recent correspondence by
Rodriguez-Coleman et al,31 benzyl alcohol was re-
ported to partition with triamcinolone crystals as a
result of its preference for a lipophilic environment.
Thus, a better control to separate the effects of benzyl
alcohol from TA would have been a preparation con-
taining the exact concentration of benzyl alcohol as
determined by high-performance liquid chromatogra-
phy from the sedimented suspensions of TA, the pro-
cedure used in our study to prepare 8-mg and 20-mg
injections.
This study was designed bearing two important
issues. First, we used pigmented rabbits because it is
known that melanin granules have affinity for certain
lipophilic drugs.32 A drug dose that is safe in an albino
eye may show detrimental effects when applied to a
pigmented eye. Therefore, the use of pigmented rab-
bits for drug toxicity studies may be more relevant to
the human eye. Second, we confined our tissue anal-
ysis to the inferior retina, where maximal drug con-
centration is expected after intravitreal injection. We
were not able to affirm that toxic changes are diffuse
on the retina, because we only analyzed a small part of
the inferior retina where the drug was confined, but
the changes we found were throughout the 5 ! 5-mm
fragments.
A possible critique of this study may be that we did
not use full-field electroretinography in our study.
Although electroretinography is a useful test in ocular
pharmacology, our personal experience is that this
examination presents variable results when trying to
detect subtle toxicity changes or localized retinal
changes confined to the drug depot. Our focus was to
show morphologic changes.
Another limitation of our study is that the actual TA
concentration was not measured before injection, and
when dealing with a suspension of crystals that settle
rapidly, the actual injected doses may not be exactly
the targeted doses. In addition, when preparing the
8-mg and 20-mg doses, we did not account for the
small loss of steroid crystals in the ejected superna-
tants. In our study, it was our goal to use a preparation
method favored in clinical practice, and we were also
aware from the report by Rodriguez-Coleman et al31
that the method used in our study, sedimentation with-
out filtration, produced the closest final dose to the
targeted dose. The more sophisticated filtration meth-
ods actually resulted in variable and consistently
lower doses than the predicted range. This was also
confirmed by Kreissig et al (Association for Research
in Vision and Ophthalmology, 2005; 4731).
This study showed dose-related toxic effects of TA
in rabbit outer retina with doses as low as 4 mg, while
lower doses, such as 0.5 mg and 1 mg, did not cause
morphologic retinal changes. Needless to say, there
are many differences, such as species differences,
ocular volume differences, and presence of intraocular
inflammation, to be taken into consideration before we
can apply these data to clinical practice. The rabbit
vitreous volume is one half to one third of that of
humans, and it is likely that a higher localized con-
centration is further achieved with the drug pocketed
within the overlying formed cortical vitreous in the
rabbit eyes. Currently, 4 mg is the most commonly
used dose of TA in intravitreal injections, but clini-
cians have used higher doses. It is possible that 4 mg
in the vitreous cavity of an inflamed human eye is
equivalent to 0.5 mg or 1 mg in the rabbit eyes and is
thus safe. Our data should caution use of higher doses
of TA and frequent repeated injections until further
long-term retinal toxicity studies are performed.
Key words: antiinflammatory agents, corticoste-
roids, intravitreal drug delivery.
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